Price T Rowe Associates Inc. MD Has $40.08 Million Position in Prestige Consumer Healthcare Inc. $PBH

Key Points

• Price T Rowe Associates Inc. MD increased its holdings in Prestige Consumer Healthcare Inc. by 2.4%, owning approximately $40.08 million worth of the company's stock.
• The company's latest earnings report showed EPS of $0.95, missing estimates by $0.06, with a revenue decline of 6.6% year-over-year.
• Analysts have generally rated the stock as a "Moderate Buy", with a consensus target price set at $93.33.

Price T Rowe Associates Inc. MD boosted its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 2.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 466,204 shares of the company's stock after purchasing an additional 11,112 shares during the quarter. Price T Rowe Associates Inc. MD owned about 0.94% of Prestige Consumer Healthcare worth $40,081,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Opal Wealth Advisors LLC acquired a new stake in Prestige Consumer Healthcare in the 1st quarter valued at $38,000. McIlrath & Eck LLC grew its stake in shares of Prestige Consumer Healthcare by 19.1% in the 4th quarter. McIlrath & Eck LLC now owns 959 shares of the company's stock worth $75,000 after acquiring an additional 154 shares in the last quarter. Costello Asset Management INC bought a new stake in shares of Prestige Consumer Healthcare in the 1st quarter worth $112,000. GAMMA Investing LLC grew its stake in shares of Prestige Consumer Healthcare by 35.9% in the 1st quarter. GAMMA Investing LLC now owns 1,879 shares of the company's stock worth $162,000 after acquiring an additional 496 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of Prestige Consumer Healthcare by 97.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,925 shares of the company's stock worth $150,000 after acquiring an additional 950 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company's stock.

Prestige Consumer Healthcare Trading Up 1.0%

Shares of PBH stock opened at $67.05 on Thursday. The stock has a market capitalization of $3.30 billion, a price-to-earnings ratio of 15.74, a PEG ratio of 2.10 and a beta of 0.43. The company's fifty day simple moving average is $74.26 and its two-hundred day simple moving average is $80.83. Prestige Consumer Healthcare Inc. has a 1 year low of $62.95 and a 1 year high of $90.04. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.38 and a quick ratio of 2.99.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.95 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.01 by ($0.06). The company had revenue of $249.53 million for the quarter, compared to analysts' expectations of $260.71 million. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The business's revenue for the quarter was down 6.6% on a year-over-year basis. During the same period last year, the company posted $0.90 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. As a group, analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Wall Street Zen lowered shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Canaccord Genuity Group reduced their target price on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Finally, Royal Bank Of Canada upgraded shares of Prestige Consumer Healthcare to a "hold" rating in a research report on Thursday, May 8th. Three research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, Prestige Consumer Healthcare currently has a consensus rating of "Moderate Buy" and a consensus target price of $93.33.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.